<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02826382</url>
  </required_header>
  <id_info>
    <org_study_id>511-0001-A</org_study_id>
    <nct_id>NCT02826382</nct_id>
  </id_info>
  <brief_title>Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041</brief_title>
  <official_title>A Preliminary Evaluation of Uptake in Bone Metastases, Biodistribution and Excretion of the Novel Radiotracer [68Ga]P15-041 by PET/CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Five Eleven Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Five Eleven Pharma, Inc.</source>
  <brief_summary>
    <textblock>
      A phase 0 study to demonstrate [68Ga]P15-041 binding to bone metastases in prostate cancer
      and determination of human dosimetry.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time course of uptake of [68Ga]P15-041 in bone metastases</measure>
    <time_frame>60 minutes post injection</time_frame>
    <description>kinetics of [68Ga]P15-041 uptake in known or suspected bone metastases in prostate cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time course of whole body distribution of [68Ga]P15-041</measure>
    <time_frame>3 hours post injection</time_frame>
    <description>whole body distribution of [68Ga]P15-041 used for human dosimetry determination</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Bone Metastases</condition>
  <arm_group>
    <arm_group_label>Dynamic imaging group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dynamic imaging of suspected bone metastases with the investigation drug [68Ga]P15-041</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Whole body dosimetry group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determination of human dosimetry of the investigation drug [68Ga]P15-041</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[68Ga]P15-041</intervention_name>
    <description>Imaging by Positron Emission Tomography after injection of [68Ga]P15-041</description>
    <arm_group_label>Dynamic imaging group</arm_group_label>
    <arm_group_label>Whole body dosimetry group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed prostate cancer. known or suspected bone metastases referred
             for a clinical [99mTc]MDP scan

        Exclusion Criteria:

          -  Estimated creatinine clearance (GFR) &lt; 30 mL/min (calculated), history of
             hyperparathyroidism, • Inability to tolerate imaging procedures in the opinion of an
             investigator or treating physician, • Any current medical condition, illness, or
             disorder as assessed by medical record review and/or self-reported that is considered
             by a physician investigator to be a condition that could compromise participant safety
             or successful participation in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthew Fillare</last_name>
    <email>Matthew.Fillare@uphs.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Fillare</last_name>
      <email>Matthew.Fillare@uphs.upenn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2016</study_first_submitted>
  <study_first_submitted_qc>July 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

